Reviewing the evidence for biosimilars: key insights, lessons learned and future horizons

por Uhlig, Till, Goll, Guro L.
Publicado 2017

A high serum level of eotaxin (CCL 11) is associated with less radiographic progression in early rheumatoid arthritis patients

por Syversen, Silje W, Goll, Guro L, Haavardsholm, Espen A, Bøyesen, Pernille, Lea, Tor, Kvien, Tore K
Publicado 2008

Rheumatoid factor and falsely elevated results in commercial immunoassays: data from an early arthritis cohort

por Gehin, Johanna E., Klaasen, Rolf A., Norli, Ellen S., Warren, David J., Syversen, Silje W., Goll, Guro L., Bjøro, Trine, Kvien, Tore K., Mjaavatten, Maria D., Bolstad, Nils
Publicado 2021

Immune response and safety in standard and third dose SARS-CoV-2 vaccination in patients with autoimmune hepatitis on immunosupressive therapy, a prospective cohort study

por Jorgensen, Kristin, Chopra, Adity, Sexton, Joseph, Tveter, Anne T, Hov, Johannes R., Jyssum, Ingrid, Nissen-Meyer, Lise Sofie H., Vaage, John T, Syversen, Silje W, Goll, Guro L, Lund-Johansen, Fridtjof, Jahnsen, Jørgen
Publicado 2022

Therapeutic drug monitoring of infliximab compared to standard clinical treatment with infliximab: study protocol for a randomised, controlled, open, parallel-group, phase IV study...

por Syversen, Silje W, Goll, Guro L, Jørgensen, Kristin K, Olsen, Inge C, Sandanger, Øystein, Gehin, Johanna E, Warren, David J, Sexton, Joseph, Mørk, Cato, Jahnsen, Jørgen, Kvien, Tore K, Bolstad, Nils, Haavardsholm, Espen A
Publicado 2020

Immunogenicity and Safety of Standard and Third‐Dose SARS–CoV‐2 Vaccination in Patients Receiving Immunosuppressive Therapy

por Syversen, Silje W., Jyssum, Ingrid, Tveter, Anne T., Tran, Trung T., Sexton, Joseph, Provan, Sella A., Mjaaland, Siri, Warren, David J., Kvien, Tore K., Grødeland, Gunnveig, Nissen‐Meyer, Lise S. H., Ricanek, Petr, Chopra, Adity, Andersson, Ane M., Kro, Grete B., Jahnsen, Jørgen, Munthe, Ludvig A., Haavardsholm, Espen A., Vaage, John T., Lund‐Johansen, Fridtjof, Jørgensen, Kristin K., Goll, Guro L.
Publicado 2022

Sa1052: IMMUNOGENICITY AND SAFETY OF STANDARD AND THIRD DOSE SARS-COV-2 VACCINATION IN PATIENTS WITH IMMUNE-MEDIATED INFLAMMATORY DISEASES; A PROSPECTIVE COHORT STUDY

por Joergensen, Kristin K., Syversen, Silje W, Jyssum, ingrid, Tveter, Anne Therese, Tran, Trung T., Sexton, Joe, Provan, Sella A., Mjaaland, Siri, Warren, David J., Kvien, Tore K., Gr⊘deland, Gunnveig, Nissen-Meyer, Lise Sofie H., Ricanek, Petr, Chopra, Adity, Anderson, Ane M., Kro, Grete B., Munthe, Ludvig A., Haavardsholm, Espen A., Vaage, John T.T., Lund-Johansen, Fridtjof, Jahnsen, Jorgen, Goll, Guro L.
Publicado 2022

Efficacy and Safety of CT-P13 in Inflammatory Bowel Disease after Switching from Originator Infliximab: Exploratory Analyses from the NOR-SWITCH Main and Extension Trials

por Jørgensen, Kristin K., Goll, Guro L., Sexton, Joe, Bolstad, Nils, Olsen, Inge C., Asak, Øivind, Berset, Ingrid P., Blomgren, Ingrid M., Dvergsnes, Katrine, Florholmen, Jon, Frigstad, Svein O., Henriksen, Magne, Hagfors, Jon, Huppertz-Hauss, Gert, Haavardsholm, Espen A., Klaasen, Rolf A., Moum, Bjørn, Noraberg, Geir, Prestegård, Ulf, Rydning, Jan H., Sagatun, Liv, Seeberg, Kathrine A., Torp, Roald, Vold, Cecilia, Warren, David J., Ystrøm, Carl M., Lundin, Knut E. A., Kvien, Tore, Jahnsen, Jørgen
Publicado 2020